{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Confirmed Positive ADA Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Confirmed Positive ADA Post-dose Only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Confirmed Positive ADA Anytime"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-treated population - all participants who received at least 1 dose of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 599 days","title":"Number of Participants With an Anti-drug Antibody (ADA) Response to Loncastuximab Tesirine","type":"SECONDARY","unitOfMeasure":"Participants"}